IXCHIQ (VLA1553)

About Valneva

Valneva is a specialty vaccine company with a mission to address unmet medical needs in infectious disease prevention. It has successfully commercialized three vaccines, including the world's first single-shot chikungunya vaccine, and is advancing a late-stage pipeline highlighted by a Lyme disease vaccine candidate developed with Pfizer. The company's strategy is built on an integrated business model, a focus on niche or neglected diseases, and strategic partnerships to maximize the value of its assets.

Therapeutic Areas